GLP-1 Drugs and Substance Use Evidence

A 2026 cardiovascular review argues that alcohol currently has the strongest human signal among substance-use outcomes studied with incretin-based medicines. The paper is a review article, not a new clinical trial, and it does not establish these drugs as addiction treatments. Its most direct semaglutide evidence comes from one small randomized phase 2 trial in 48 adults with alcohol use disorder.^{[1] [2]}

That evidence is relevant to readers following semaglutide, but the boundary is narrow. The review combines randomized trials with electronic health record analyses and findings for other GLP-1 receptor agonists. Those designs answer different questions and should not be merged into a single claim that GLP-1 medicines reduce substance use.

The 2026 paper is a review, not a trial

The Journal of Cardiovascular Pharmacology labels the focal paper a review article. Its abstract surveys human evidence on alcohol, tobacco and selected acute substance-related events across GLP-1 receptor agonists and dual incretin agonists. The authors describe the literature as molecule-specific and call evidence beyond alcohol and tobacco preliminary.^[1]

No participants were enrolled for this publication. It reports no new intervention arm, comparison group or patient-level outcome. Its contribution is synthesis: it asks whether medicines already used for cardiometabolic conditions might also affect behaviors that carry cardiovascular risk. That framing can guide research, but it cannot supply an effect estimate of its own.

The paper also discusses dual incretin agonists as a class, yet its abstract says tirzepatide-specific evidence remains preliminary. Evidence from semaglutide or exenatide cannot be assigned to tirzepatide merely because the medicines share part of their receptor biology.

The randomized alcohol evidence is early

The strongest semaglutide study cited by the review was a nine-week, double-blind phase 2 trial. Investigators randomized 48 non-treatment-seeking adults with alcohol use disorder to once-weekly semaglutide or placebo. The primary outcome was alcohol consumed during a laboratory self-administration task rather than abstinence, hospitalization or a cardiovascular event.^[2]

Semaglutide reduced grams of alcohol consumed in that laboratory task, with a standardized estimate of minus 0.48 and a 95% confidence interval from minus 0.85 to minus 0.11. It also reduced drinks per drinking day and weekly craving. The trial did not find a change in average drinks per calendar day or the number of drinking days.^[2] A positive result on selected outcomes is therefore not the same as proof of broad clinical effectiveness for alcohol use disorder.

An earlier randomized trial tested exenatide rather than semaglutide in 127 treatment-seeking people with alcohol use disorder. Exenatide did not significantly reduce the primary outcome, the number of heavy drinking days, compared with placebo over 26 weeks. An exploratory subgroup analysis suggested fewer heavy drinking days among participants with obesity, but subgroup findings require confirmation.^[3]

The contrast between these two trials is useful. They studied different medicines, populations, durations and endpoints. The semaglutide result should not erase the neutral primary outcome in the exenatide trial, while the exenatide result does not disprove the semaglutide signal.

Tobacco findings mix a pilot trial with records

The randomized tobacco evidence comes from a six-week pilot trial of exenatide added to nicotine patches and brief cessation counseling. Eighty-four prediabetic or overweight smokers were randomized. Seven-day abstinence was 46.3% with exenatide and 26.8% with placebo, with a risk ratio of 1.70 and a 95% credible interval from 0.96 to 3.27.^[4]

This was a small study in a selected population, and every participant received nicotine replacement plus counseling. The result does not show that exenatide alone causes smoking cessation. It also does not establish a semaglutide effect, since the tested molecule was exenatide.

A separate target-trial emulation used electronic health records from people with type 2 diabetes and tobacco use disorder. Among 222,942 new users of diabetes medicines, including 5,967 semaglutide users, semaglutide was associated with fewer medical encounters coded for tobacco use disorder than seven comparator medicine groups. The hazard ratio ranged from 0.68 versus insulin to 0.88 versus other GLP-1 receptor agonists.^[5]

That analysis did not measure current smoking behavior, and the authors listed documentation bias, residual confounding and missing adherence data among its limitations.^[5] Fewer coded encounters can reflect a treatment effect, differences between patient groups or differences in healthcare documentation. An observational association cannot decide among those explanations on its own.

Cardiovascular relevance does not prove benefit

Alcohol and tobacco use can affect cardiovascular risk, so cardiologists have a reason to follow this research. The studies summarized here did not test whether a substance-use effect from an incretin medicine prevents heart attack, stroke or cardiovascular death. The focal review raises that clinical question; it does not answer it.

Readers should also separate established indications from experimental hypotheses. The semaglutide evidence overview covers the drug's clinical evidence, while the semaglutide regulation section tracks approved status by jurisdiction. Neither page turns an early alcohol or tobacco signal into an approved addiction indication.

These findings also do not support changing, starting or stopping a prescribed medicine without clinical guidance. Substance use disorders have evidence-based treatments, and a small experimental study does not replace individual assessment or established care.

What the evidence still needs

Larger randomized trials need to test clinically meaningful outcomes over longer follow-up. For alcohol, that means confirming whether changes in laboratory consumption and craving lead to fewer heavy-drinking days, sustained remission or fewer acute events. For tobacco, trials need to measure verified abstinence and separate any medicine effect from counseling and nicotine replacement.

Future work must also test each molecule directly. Semaglutide, exenatide and dual agonists should not be treated as interchangeable. Trials should report adverse events, discontinuation and whether effects differ by obesity, diabetes status or baseline substance use without leaning on underpowered subgroup findings.

The 2026 review is best read as an evidence map. It identifies a credible alcohol signal, thinner tobacco evidence and preliminary findings elsewhere. The underlying primary research supports more trials, not a new treatment claim.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.